Drug interactions of Prozac vs. Xanax. Do not use an MAO inhibitor (MAOI, or monoamine oxidase inhibitor) within 14 days of Prozac. The combination may increase the risk of serotonin syndrome, a life-threatening medical emergency due to excess serotonin.
Monoamine oxidase (MAO) inhibitors are a class of one such naturally occurring compounds that have been clinically developed as an antidepressant and as a treatment for social anxiety and Parkinson's disease (Youdim et al., 2006; Finberg and Rabey, 2016; Menkes et al., 2016; Tipton, 2018; Sabri and Saber-Ayad, 2020).
Prozac is the brand name of the drug fluoxetine, a selective serotonin reuptake inhibitor (SSRI). SSRIs are second-generation antidepressants, which means they are newer than first-generation medications such as monoamine oxidase inhibitors (MAOIs) or tricyclic antidepressants (TCAs).
Compared to classical tricyclic antidepressants, Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine. In addition, Bupropion does not inhibit monoamine oxidase.
The S-enantiomer of omeprazole, esomeprazole, has recently also been described as an inhibitor of monoamine oxidase-A (MAO-A), the main enzyme responsible for 5-HT degradation, albeit with lower potency compared to the effect on TPH1 and TPH2.
MAO-A was inhibited by the following drugs: pargyline > clorgyline > iproniazid > fluoxetine > desipramine > amitriptyline > imipramine > citalopram > venlafaxine > reboxetine > olanzapine > mirtazapine > tianeptine > moclobemide, cocaine >> lithium, valproate.
Although SSRIs are the current frontline treatment for depression, MAOIs (monoamine oxidase inhibitors) were the first antidepressants developed. They are typically more potent than SSRIs because they affect more neurotransmitters, and they can cause more side effects.
Particular safety concerns arise when monoamine oxidase inhibiting (MAOI) drugs and dextromethorphan are coadministered. In addition to adverse drug reactions, the safety profile of dextromethorphan is affected by episodic and sporadic abuse.
At least 14 days must elapse between discontinuation of a monoamine oxidase inhibitor (MAOI) antidepressant and initiation of ZOLOFT. In addition, at least 14 days must elapse after stopping ZOLOFT before starting an MAOI antidepressant [See CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS].
Jan 22, 2022
Selegiline, a selective monoamine oxidase B inhibitor, has been approved for the adjunctive treatment of Parkinson's disease at low doses.
Rasagiline (Azilect) is a highly selective and potent propargylamine inhibitor of monoamine oxidase (MAO) type B.
Sertraline is a type of antidepressant known as a selective serotonin reuptake inhibitor (SSRI). It's often used to treat depression, and also sometimes panic attacks, obsessive compulsive disorder (OCD) and post-traumatic stress disorder (PTSD).
Do not take selegiline if you have used narcotic pain medicines (including meperidine, methadone, tramadol, Demerol®, Dolophine®, Ultram®) or an MAO inhibitor (MAOI) (eg, isocarboxazid, linezolid, phenelzine, tranylcypromine, Marplan®, Nardil®, Parnate®, Zyvox®) within the past 14 days.
Rasagiline is about 10 times more potent in the inhibition of MAO-B than selegiline in ex vivo studies. This higher potency of rasagiline is corrected in the clinic with dose adjustments (approved daily dose 1 and 5–10 mg for rasagiline and selegiline, respectively).
Selegiline is available under the following different brand names: Eldepryl and Zelapar.
Modafinil, also known as Provigil, is a medication used to treat sleepiness caused by narcolepsy, shift work sleep disorder, or obstructive sleep apnea. It decreases excessive sleepiness caused by narcolepsy and other sleep disorders, obstructive sleep apnea.
Modafinil is classified by the United States FDA as a schedule IV controlled substance, a category for drugs with valid medical uses and low addiction potential. The International Narcotics Control Board does not consider modafinil a narcotic nor a psychotropic substance.
For both subgroups, all three depression rating scales showed a significant improvement following 2 weeks and 3 months of modafinil treatment. This chart review provides preliminary evidence that modafinil treatment may be beneficial to those with major depression, even when unresponsive to other treatments.
The recommended dose for modafinil is 200mg taken once daily . Modafinil has been found to be well-tolerated, with a low incidence of adverse effects and low potential for abuse .